Massachusetts medical device maker Cognoptix launched a clinical trial of its Sapphire II eye exam, assessing its potential for diagnosing early stages of Alzheimer’s disease by detecting certain biomarkers in the eye.
The non-invasive exam looks for traces of beta amyloid peptides, a hallmark of Alzheimer’s disease which grows in parallel in the eye as well as in the brain, according to the company.